The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

Attention-deficit/hyperactivity disorder (ADHD) is a common but complex neurodevelopmental condition characterized by symptoms of inattention, hyperactivity, and ...

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...

Long-term methylphenidate use in childhood links to higher adult BMI and slightly shorter height, underscoring the need for ...

ADHD New Zealand spokesperson Darrin Bull joins Mike Hosking to discuss the significant prescription law change that will make ADHD treatment easier to acc ...

In a groundbreaking move, the Allan government in Victoria has announced that general practitioners (GPs) will soon be able to diagnose and treat Attention Deficit Hyperactivity Disorder (ADHD) for ...

Boys who stopped ADHD treatment at higher risk for negative consequences. Oct. 16, 2012 — -- Young boys who discontinue treatment for attention deficit hyperactivity disorder (ADHD) are featured ...

ADHD is a neurological condition that impacts millions of Australians, with estimates suggesting that between 6 and 10 percent of children and adolescents, and 2 to 6 percent of adults are affected.